Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.56 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27788117 | 0.92 | POLB (0.60) | POLBHSD17B10FFAR1APLNR | |
| SCHEMBL4419943 | 0.89 | POLB (0.57) | POLBHSD17B10APLNR | |
| SCHEMBL10784792 | 0.88 | POLB (0.55) | POLBHSD17B10APLNRNPC1PKM | |
| SCHEMBL8714213 | 0.88 | POLB (0.56) | POLBHSD17B10APLNRALDH1A1 | |
| SCHEMBL10767355 | 0.88 | POLB (0.56) | POLBHSD17B10APLNRALDH1A1 | |
| SCHEMBL491188 | 0.87 | HSD17B10 (0.71) | POLBHSD17B10 | |
| SCHEMBL30436820 | 0.87 | HSD17B10 (0.71) | POLBHSD17B10 | |
| SCHEMBL266527 | 0.87 | NPC1 (0.58) | POLBHSD17B10APLNRNPC1PKM | |
| SCHEMBL585472 | 0.85 | APLNR (0.56) | POLBAPLNRNPC1PKMRAB9A | |
| SCHEMBL2398226 | 0.85 | POLB (0.53) | POLBHSD17B10APLNRNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112682031-B | Oil field interwell tracer, tracing method and fracturing fluid | 中国石油化工股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11746364-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-09-05 | — | — | US | disclosed |
| US-11739354-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-20220002769-A1 | ENZYMATIC SYNTHESIS OF KAVALACTONES AND FLAVOKAVAINS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002768-A1 | ENZYMATIC SYNTHESIS OF KAVALACTONES AND FLAVOKAVAINS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-06 | — | — | US | disclosed |
| US-10941429-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | disclosed |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| EP-1871339-A1 | UV PROTECTION | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871735-A1 | ANTIOXIDANTS | Merck Patent GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006111233-A1 | ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006111234-A1 | UV PROTECTION | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5066658-A | Enzyme Inhibitors; Bronchodilators; Antiinflammatory Agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | POLB 259/4885HSD17B10 364/4885FFAR1 3180/4885 |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | POLB 3555/4885HSD17B10 1647/4885FFAR1 713/4885 |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | HPD, HAAO, UGT1A6 | POLB 236/4885HSD17B10 699/4885FFAR1 3333/4885 |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | POLB 3555/4885HSD17B10 1647/4885FFAR1 713/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | POLB 3555/4885HSD17B10 1647/4885FFAR1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.